Lantern Pharma, Inc. (LTRN)

Over the past six months, Lantern Pharma's stock experienced several impacts. In August 2025, the company reported its second-quarter financial results and business updates, including the successful completion of enrollment for the LP-184 Phase 1a clinical trial. In September 2025, Lantern Pharma announced that its Phase 1a study of LP-184 met all primary endpoints in advanced solid tumors. In November 2025, the company reported its third-quarter financial results, showing a narrowed net loss compared to the previous year. In December 2025, Lantern Pharma reported additional positive LP-184 Phase 1a results. In January 2026, the company announced the establishment of an AI Center of Excellence in Bengaluru, India. As of January 6, 2026, the share price was $3.45, representing a decline of 16.26% from January 7, 2025.

Lantern Pharma is a clinical-stage biopharmaceutical company that does not yet generate revenue from selling approved drugs, so traditional demand seasonality is not directly applicable. Analysis of LTRN stock's seasonal chart over the past four years suggests a potential seasonal pattern for the stock itself, with a "Buy Date" of October 31 and a "Sell Date" of March 22 historically resulting in a geometric average return of 28.94% above the S&P 500 Total Return Index.

Lantern Pharma, Inc. is a clinical-stage biopharmaceutical company focused on transforming oncology drug discovery and development through AI and ML. Their core technology is the RADR® AI platform, which uses oncology-focused data and ML algorithms to identify drug candidates, predict patient responses, and design clinical trials. The company's pipeline includes LP-300 in Phase 2 trials for non-small cell lung cancer, LP-184 in Phase 1 trials for solid tumors with FDA Fast Track and Rare Pediatric Disease Designations, LP-284 in Phase 1 trials for non-Hodgkin's lymphomas, STAR-001 in preclinical development for CNS cancers, and an ADC program for cancer treatment.

Lantern Pharma is headquartered in Dallas, Texas, and has expanded its global development opportunities by establishing an AI Center of Excellence in Bengaluru, India. Clinical trials for its LP-300 program have advanced in Asia, with a Japanese cohort completing enrollment across multiple centers in Japan.

Lantern Pharma's brand reputation has been positively influenced by positive Phase 1a data for LP-184, FDA Designations for LP-184, the expansion of its RADR® AI platform, and analyst coverage from Lake Street.

Lantern Pharma, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional investors hold approximately 15.92% to 28.62% of the company's stock. Insiders own approximately 8.50% to 19.24% of the stock. Retail investors hold a significant portion, with some reports indicating around 61.43% of the stock.